Literature DB >> 25234675

Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation.

Miguel Jerez-Valero1, Marina Urena1, John G Webb2, Corrado Tamburino3, Antonio J Munoz-Garcia4, Asim Cheema5, Antonio E Dager6, Vicenç Serra7, Ignacio J Amat-Santos8, Marco Barbanti9, Sebastiano Immè3, Juan H Alonso Briales4, Hatim Al Lawati5, Luis Miguel Benitez6, Angela Maria Cucalon6, Bruno Garcia del Blanco7, Ana Revilla8, Eric Dumont1, Henrique Barbosa Ribeiro1, Luis Nombela-Franco1, Sébastien Bergeron1, Philippe Pibarot1, Josep Rodés-Cabau10.   

Abstract

OBJECTIVES: The aim of this study was to determine the impact of the degree of residual aortic regurgitation (AR) and acuteness of presentation of AR after transcatheter aortic valve replacement (TAVR) on outcomes.
BACKGROUND: The degree of residual AR after TAVR leading to excess mortality remains controversial, and little evidence exists on the impact of the acuteness of presentation of AR.
METHODS: A total of 1,735 patients undergoing TAVR with balloon-expandable or self-expanding valves were included. The presence and degree of AR were evaluated by transthoracic echocardiography; acute AR was defined as an increase in AR severity of ≥1 degree compared with pre-procedural echocardiography.
RESULTS: Residual AR was classified as mild in 761 patients (43.9%) and moderate to severe in 247 patients (14.2%). The presence of moderate to severe AR was an independent predictor of mortality at a mean follow-up of 21 ± 17 months compared with none to trace (adjusted hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.32 to 2.48; p < 0.001) and mild AR (adjusted HR: 1.68, 95% CI: 1.27 to 2.24; p < 0.001) groups. There was no increased risk in patients with mild AR compared with those with none to trace AR (p = 0.393). In patients with moderate to severe AR, acute AR was observed in 161 patients (65%) and chronic AR in 86 patients (35%). Acute moderate to severe AR was independently associated with increased risk of mortality compared with none/trace/mild AR (adjusted HR: 2.37, 95% CI: 1.53 to 3.66; p < 0.001) and chronic moderate to severe AR (adjusted HR: 2.24, 95% CI: 1.17 to 4.30; p = 0.015) [corrected]. No differences in survival rate were observed between patients with chronic moderate to severe and none/trace/mild AR (p > 0.50).
CONCLUSIONS: AR occurred very frequently after TAVR, but an increased risk of mortality at ∼2-year follow-up was observed only in patients with acute moderate to severe AR.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute aortic regurgitation; aortic regurgitation; mitral regurgitation; paravalvular leak; transcatheter aortic valve implantation; transcatheter aortic valve replacement

Mesh:

Year:  2014        PMID: 25234675     DOI: 10.1016/j.jcin.2014.04.012

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  12 in total

1.  Modern Use of Echocardiography in Transcatheter Aortic Valve Replacement: an Up-Date.

Authors:  Cristina Caldararu; Serban Balanescu
Journal:  Maedica (Bucur)       Date:  2016-12

Review 2.  Paravalvular Leaks-From Diagnosis to Management.

Authors:  Samuel Bernard; Evin Yucel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-14

3.  Impact of Mitral Regurgitation on Clinical Outcomes After Transcatheter Aortic Valve Implantation.

Authors:  Crochan J O'Sullivan; David Tüller; Rainer Zbinden; Franz R Eberli
Journal:  Interv Cardiol       Date:  2016-05

4.  The Impact of Self-Expandable Transcatheter Aortic Valve Replacement on Concomitant Functional Mitral Regurgitation: A Comprehensive Engineering Analysis.

Authors:  Andrés Caballero; Wenbin Mao; Raymond McKay; Wei Sun
Journal:  Struct Heart       Date:  2020-04-03

5.  Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: A single-center experience.

Authors:  Fadi J Sawaya; Marco Spaziano; Thierry Lefèvre; Andrew Roy; Phillippe Garot; Thomas Hovasse; Antoinette Neylon; Hakim Benamer; Mauro Romano; Thierry Unterseeh; Marie-Claude Morice; Bernard Chevalier
Journal:  World J Cardiol       Date:  2016-12-26

6.  Transcatheter aortic valve implantation: General anesthesia using transesophageal echocardiography does not decrease the incidence of paravalvular leaks compared to sedation alone.

Authors:  Cédrick Zaouter; Sara Smaili; Lionel Leroux; Guillaume Bonnet; Sébastien Leuillet; Alexandre Ouattara
Journal:  Ann Card Anaesth       Date:  2018 Jul-Sep

Review 7.  Spotlight on the SAPIEN 3 transcatheter heart valve.

Authors:  Tobias Rheude; Johannes Blumenstein; Helge Möllmann; Oliver Husser
Journal:  Med Devices (Auckl)       Date:  2018-10-01

Review 8.  TAVR: A Review of Current Practices and Considerations in Low-Risk Patients.

Authors:  Jenna Spears; Yousif Al-Saiegh; David Goldberg; Sina Manthey; Sheldon Goldberg
Journal:  J Interv Cardiol       Date:  2020-12-24       Impact factor: 2.279

9.  Early mortality and safety after transcatheter aortic valve replacement using the SAPIEN 3 in nonagenarians.

Authors:  Eiji Ichimoto; Adam Arnofsky; Michael Wilderman; Richard Goldweit; Joseph De Gregorio
Journal:  J Geriatr Cardiol       Date:  2018-06       Impact factor: 3.327

10.  Insights into permanent pacemaker implantation following TAVR in a real-world cohort.

Authors:  Tobias Tichelbäcker; Leonard Bergau; Miriam Puls; Tim Friede; Tobias Mütze; Lars Siegfried Maier; Norbert Frey; Gerd Hasenfuß; Markus Zabel; Claudius Jacobshagen; Samuel Sossalla
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.